MCL1 and melanoma: Specifically, a pre-clinical study in BRAFV600E melanoma demonstrated synergistic induction of apoptosis when BRAF or MEK inhibitors were combined with a MCL-1 inhibitor, which aligned with MCL-1 being the predominant pro-survival protein expressed in melanoma cells [17].